Literature DB >> 3018738

Interferon gamma and granulocyte/macrophage colony-stimulating factor inhibit growth and induce antigens characteristic of myeloid differentiation in small-cell lung cancer cell lines.

M R Ruff, W L Farrar, C B Pert.   

Abstract

The expression of several macrophage and hemopoietic cell surface markers recently described on small-cell lung cancer (SCLC) cell lines was studied by use of flow cytometry. The antigens Leu-M3, Leu-7, and HLA-DR were examined for their modulation by human interferon gamma and granulocyte/macrophage colony-stimulating factor (GM-CSF). Both of these lymphokines generally induced enhanced expression of hemopoietic markers in several SCLC lines. A differential response to these two hormones was observed, in that qualitative and quantitative differences in marker modulation among the tested cell lines were apparent. In addition to regulating the antigenic phenotype of these cells, both interferon gamma and GM-CSF had antiproliferative effects on SCLC lines as determined by [3H]thymidine incorporation and clonal growth in agar. These results suggest that interferon gamma and GM-CSF promote a differentiation process in SCLC cell lines that has characteristics in common with myeloid differentiation. These findings support the theory that SCLC tumors are hemopoietic cells that arise from macrophages or their precursors and suggest new therapeutic modalities for the treatment of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018738      PMCID: PMC386554          DOI: 10.1073/pnas.83.17.6613

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Origin of human small cell lung cancer.

Authors:  M R Ruff; C B Pert
Journal:  Science       Date:  1985-08-16       Impact factor: 47.728

2.  Origin of human small cell lung cancer.

Authors:  A F Gazdar; P A Bunn; J D Minna; S B Baylin
Journal:  Science       Date:  1985-08-16       Impact factor: 47.728

3.  Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1).

Authors:  E S Kawasaki; M B Ladner; A M Wang; J Van Arsdell; M K Warren; M Y Coyne; V L Schweickart; M T Lee; K J Wilson; A Boosman
Journal:  Science       Date:  1985-10-18       Impact factor: 47.728

4.  Distinct activities of interferon-gamma, lymphokine and cytokine differentiation-inducing factors acting on the human monoblastic leukemia cell line U937.

Authors:  P E Harris; P Ralph; P Litcofsky; M A Moore
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

5.  Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro.

Authors:  E C Bradley; F W Ruscetti
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

6.  Increased survival in mice inoculated with tumor cells and treated with interferon preparations.

Authors:  I Gresser; C Bourali; J P Lévy; D Fontaine-Brouty-Boyé; M T Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1969-05       Impact factor: 11.205

7.  Hematopoietic cell surface markers on metastatic small cell carcinoma detected with monoclonal antibodies.

Authors:  B J Patterson; J B Robinson; P H Pinkerton
Journal:  Am J Clin Pathol       Date:  1985-08       Impact factor: 2.493

8.  Recombinant interferon-gamma increases HLA-DR synthesis and expression.

Authors:  T Y Basham; T C Merigan
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

9.  Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors.

Authors:  R N Moore; J J Oppenheim; J J Farrar; C S Carter; A Waheed; R K Shadduck
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

10.  Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity.

Authors:  P S Steeg; R N Moore; H M Johnson; J J Oppenheim
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more
  12 in total

1.  Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant.

Authors:  S P Cole; B M Campigotto; J G Johnson; B E Elliott
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.

Authors:  P Ragnhammar
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

3.  Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin.

Authors:  S Dedhar; L Gaboury; P Galloway; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 4.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

5.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

6.  Modulation of in vitro cell growth of human and murine urothelial tumor cell lines under the influence of interleukin-3, granulocyte-, macrophage- and granulocyte-colony-stimulating factor.

Authors:  T Block; F Schmid; B Geffken; U Treiber; R Busch; R Hartung
Journal:  Urol Res       Date:  1992

7.  Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.

Authors:  E J Derbyshire; R A Stahel; E J Wawrzynczak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

8.  Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.

Authors:  Yefim Manevich; Leticia Reyes; Carolyn D Britten; Danyelle M Townsend; Kenneth D Tew
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

Review 9.  Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.

Authors:  Martin R Jadus; Josephine Natividad; Anthony Mai; Yi Ouyang; Nils Lambrecht; Sandor Szabo; Lisheng Ge; Neil Hoa; Maria G Dacosta-Iyer
Journal:  Clin Dev Immunol       Date:  2012-07-29

10.  Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer.

Authors:  Inès Dufait; Julia Katharina Schwarze; Therese Liechtenstein; Wim Leonard; Heng Jiang; David Escors; Mark De Ridder; Karine Breckpot
Journal:  Oncotarget       Date:  2015-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.